Milan KoÅ¾Ã-Å¡ek

List of Publications by Year
in descending order

45 papers	1,425 citations	361296 20 h-index	330025 37 g-index
54 all docs	54 docs citations	54 times ranked	1830 citing authors

#	Article	IF	Citations
1	structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor. Antiviral Research, 2021, 185, 104971.	1.9	5
2	Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase. Molecules, 2021, 26, 1007.	1.7	8
3	Proteinâ€“Ligand Interactions in the STING Binding Site Probed by Rationally Designed Single-Point Mutations: Experiment and Theory. Biochemistry, 2021, 60, 607-620.	1.2	15
4	Ligand Strain and Its Conformational Complexity Is a Major Factor in the Binding of Cyclic Dinucleotides to STING Protein. Angewandte Chemie - International Edition, 2021, 60, 10172-10178.	7.2	22
5	Ligand Strain and Its Conformational Complexity Is a Major Factor in the Binding of Cyclic Dinucleotides to STING Protein. Angewandte Chemie, 2021, 133, 10260-10266.	1.6	3
6	Synthesis and In Vitro Evaluation of C-7 and C-8 Luteolin Derivatives as Influenza Endonuclease Inhibitors. International Journal of Molecular Sciences, 2021, 22, 7735.	1.8	7
7	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112754.	2.6	21
8	Rhomboid intramembrane protease YqgP licenses bacterial membrane protein quality control as adaptor of FtsH <scp>AAA</scp> protease. EMBO Journal, 2020, 39, e102935.	3.5	35
9	Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1. Bioorganic and Medicinal Chemistry, 2019, 27, 2935-2947.	1.4	15
10	DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. Biochemical Journal, 2018, 475, 3847-3860.	1.7	5
11	Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus. Viruses, 2018, 10, 339.	1.5	17
12	Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. Scientific Reports, 2016, 6, 30443.	1.6	46
13	Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza. European Journal of Medicinal Chemistry, 2016, 121, 100-109.	2.6	9
14	Functional and Structural Characterization of Novel Type of Linker Connecting Capsid and Nucleocapsid Protein Domains in Murine Leukemia Virus. Journal of Biological Chemistry, 2016, 291, 20630-20642.	1.6	7
15	Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family. Scientific Reports, 2016, 6, 33671.	1.6	44
16	Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3487-3490.	1.0	4
17	Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds. Journal of Medicinal Chemistry, 2016, 59, 545-558.	2.9	39
18	Preorganization of the catalytic Zn2+-binding site in the HNH nuclease motifâ€”A solution study. Journal of Inorganic Biochemistry, 2015, 151, 143-149.	1.5	8

#	Article	IF	Citations
19	Re-Evaluation of Binding Properties of Recombinant Lymphocyte Receptors NKR-P1A and CD69 to Chemically Synthesized Glycans and Peptides. International Journal of Molecular Sciences, 2014, 15, 1271-1283.	1.8	8
20	Fine tuning of the catalytic activity of colicin E7 nuclease domain by systematic Nâ€terminal mutations. Protein Science, 2014, 23, 1113-1122.	3.1	9
21	Substrate binding activates the designed triple mutant of the colicin E7 metallonuclease. Journal of Biological Inorganic Chemistry, 2014, 19, 1295-1303.	1.1	6
22	GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid Insertions. Journal of Virology, 2014, 88, 3586-3590.	1.5	9
23	Thermodynamic and structural analysis of <scp>HIV</scp> protease resistance to darunavirÂâ€“Âanalysis of heavily mutated patientâ€derived <scp>HIV</scp>â€i proteases. FEBS Journal, 2014, 281, 1834-1847.	2.2	48
24	Thermodynamic characterization of the peptide assembly inhibitor binding to HIV-1 capsid protein. Retrovirology, 2013, 10, .	0.9	1
25	Chasing shadows: What determines DTI metrics in gray matter regions? An in vitro and in vivo study. Journal of Magnetic Resonance Imaging, 2013, 38, 1103-1110.	1.9	36
26	Mutations in HIV-1gagandpolCompensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease. Antimicrobial Agents and Chemotherapy, 2012, 56, 4320-4330.	1.4	40
27	Structure-Aided Design of Novel Inhibitors of HIV Protease Based on a Benzodiazepine Scaffold. Journal of Medicinal Chemistry, 2012, 55, 10130-10135.	2.9	53
28	Urea and Guanidinium Induced Denaturation of a Trp-Cage Miniprotein. Journal of Physical Chemistry B, 2011, 115, 8910-8924.	1.2	56
29	Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. Journal of Virology, 2009, 83, 8810-8818.	1.5	43
30	Backbone 1H, 13C, and 15N NMR assignment for the inactive form of the retroviral protease of the murine intracisternal A-type particle, inMIA-14 PR. Biomolecular NMR Assignments, 2009, 3, 261-264.	0.4	4
31	Structureâ^'Activity Study of New Inhibitors of Human Betaine-Homocysteine S-Methyltransferase. Journal of Medicinal Chemistry, 2009, 52, 3652-3665.	2.9	10
32	Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes. Journal of Medicinal Chemistry, 2009, 52, 7132-7141.	2.9	132
33	Stabilization of antibody structure upon association to a human carbonic anhydrase IX epitope studied by Xâ€ray crystallography, microcalorimetry, and molecular dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1275-1287.	1.5	27
34	Molecular Design of Specific Metalâ€Binding Peptide Sequences from Protein Fragments: Theory and Experiment. Chemistry - A European Journal, 2008, 14, 7836-7846.	1.7	16
35	Anomalous adsorptive properties of HIV protease: Indication of two-dimensional crystallization?. Colloids and Surfaces B: Biointerfaces, 2008, 64, 145-149.	2.5	3
36	Crystal structures of the effectorâ€binding domain of repressor Central glycolytic gene Regulator from Bacillus subtilis reveal ligandâ€induced structural changes upon binding of several glycolytic intermediates. Molecular Microbiology, 2008, 69, 895-910.	1.2	28

#	Article	IF	Citations
37	Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Research, 2008, 78, 275-277.	1.9	7
38	Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Science, 2008, 17, 1555-1564.	3.1	24
39	Inorganic Polyhedral Metallacarborane Inhibitors of HIV Protease: A New Approach to Overcoming Antiviral Resistance. Journal of Medicinal Chemistry, 2008, 51, 4839-4843.	2.9	90
40	Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region. Journal of Virology, 2008, 82, 5869-5878.	1.5	39
41	Molecular Analysis of the HIV-1 Resistance Development: Enzymatic Activities, Crystal Structures, and Thermodynamics of Nelfinavir-resistant HIV Protease Mutants. Journal of Molecular Biology, 2007, 374, 1005-1016.	2.0	74
42	Tetraphenylporphyrin-cobalt(III) Bis(1,2-dicarbollide) Conjugates:Â From the Solution Characteristics to Inhibition of HIV Protease. Journal of Physical Chemistry B, 2007, 111, 4539-4546.	1.2	38
43	Dispersion Interactions Govern the Strong Thermal Stability of a Protein. Chemistry - A European Journal, 2007, 13, 9022-9027.	1.7	29
44	From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15394-15399.	3.3	279
45	Characterisation of Mutated Proteinases Derived from HIV-Positive Patients: Enzyme Activity, Vitality and Inhibition. Collection of Czechoslovak Chemical Communications, 2004, 69, 703-714.	1.0	6